Больова форма діабетичної невропатії та її лікування прегабаліном

Автор(и)

  • О. О. Хаустова Національний медичний університет імені О.О. Богомольця, Ukraine

DOI:

https://doi.org/10.24026/1818-1384.2(58).2017.105628

Ключові слова:

діабетична невропатія, невропатичний біль, профілактика, терапія, прегабалін

Анотація

Огляд присвячено проблемі больової діабетичної невропатії, розглянуто її поширеність серед хворих на цукровий діабет 1 та 2 типів, досягнення у вивченні етіопатогенезу, наявні в даний час можливості лікування. Найпоширенішою клінічною формою діабетичної невропатії є симетрична периферична невропатія (ДСПН), яка вражає близько 20% хворих на цукровий діабет 1 типу за тривалості захворювання 20 років та до 50% пацієнтів із цукровим діабетом 2 типу після 10 років прогресування захворювання. На даний час єдині доступні підходи до лікування ДСПН – це покращення контролю глікемії та терапія болю. Встановлено високі рівні доказів на підтримку застосування деяких антиконвульсантів (прегабалін, габапентин) та антидепресантів (дулоксетин, венлафаксин, амітриптилін) для лікування невропатичного болю. Комбінована терапія болю вивчена не достатньо, тому наразі керівництва рекомендують розпочинати лікування з монотерапії одним із препаратів першої лінії, титруючи його до досягнення терапевтичної дози за умови доброї переносимості.

Біографія автора

О. О. Хаустова, Національний медичний університет імені О.О. Богомольця

Хаустова О.О., д.мед.н., професор, професор кафедри психосоматичної медицини і психотерапії

Посилання

Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. https://doi.org/10.2337/dc16-2042

Lezhenko HO. Diabetychna neiropatiia: pohliad na problemu ta mozhlyvi shliakhy yiyi rozviazannia [Diabetic neuropathy: view on the problem and possible approaches to solution]. Dyt. Likar. 2009;1:42-54. [Ukrainian].

Dyck PJB, Dyck PJ. Diabetic neuropathy. In: Dyck PJ, Thomas PK, editors. Diabetic neuropathy. 2nd ed. Philadelphia: W.B. Saunders Company; 1999. p. 255-278.

Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004 Jan 15;61(2):160-173.

Ziegler D. Painful diabetic neuropathy. Diabetes Care. 2009 Nov; 32(Suppl 2): S414–S419. https://doi.org/10.2337/dc09-s350

Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia. 2005 May;48(5):805-807. https://doi.org/10.1007/s00125-005-1721-7

Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-986. https://doi.org/10.1056/nejm199309303291401

Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995 Dec;38(6):869-880. https://doi.org/10.1002/ana.410380607

Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism. 1996 Dec;45(12):1508-1513. https://doi.org/10.1016/s0026-0495(96)90180-8

Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012 Jun;11(6):521-534. https://doi.org/10.1016/s1474-4422(12)70065-0

Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 Aug 7;376(9739):419-430. https://doi.org/10.1016/s0140-6736(10)60576-4

Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep (2014) 14: 528. https://doi.org/10.1007/s11892-014-0528-7

Martin CL, Albers JW, Pop-Busui R, and for the DCCT/ EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014 Jan; 37(1):31-38. https://doi.org/10.2337/dc13-2114

Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-393. https://doi.org/10.1056/nejmoa021778

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. https://doi.org/10.1056/nejmoa012512

Balducci S, Iacobellis G, Parisi L, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006 Jul-Aug;20(4):216-223. https://doi.org/10.1016/j.jdiacomp.2005.07.005

Singleton JR, Marcus RL, Jackson JE, et al. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014 Oct;1(10):844-849. https://doi.org/10.1002/acn3.125

Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. https://doi.org/10.1007/s11910-014-0473-5

Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O'Brien PC, Russell JW; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011 Oct;27(7):620-628. https://doi.org/10.1002/dmrr.1226

Biessels GJ, Bril V, Calcutt NA, et al. Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst. 2014 Jun;19(2):77-87. https://doi.org/10.1111/jns5.12072

O'Brien PD, Hinder LM, Sakowski SA, Feldman EL. ER stress in diabetic peripheral neuropathy: a new therapeutic target. Antioxid Redox Signal. 2014 Aug 1;21(4):621-633. https://doi.org/10.1089/ars.2013.5807

Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011 Sep 13;7(10):573-583. https://doi.org/10.1038/nrneurol.2011.137

Zenker J, Ziegler D, Chrast R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013 Aug;36(8):439-449. https://doi.org/10.1016/j.tins.2013.04.008

Boulton AJ, Valensi P, Tesfaye S. International Neuropathy Workshop of 2009: Introduction to the final reports. Diabetes/metabolism research and reviews. Diabetes Metab Res Rev. 2011 Oct;27(7):617-619. https://doi.org/10.1002/dmrr.1228

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005 Apr;28(4):956-962. https://doi.org/10.2337/diacare.28.4.956

Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993 Feb;36(2):150-154. https://doi.org/10.1007/bf00400697

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-853. https://doi.org/10.1016/s0140-6736(98)07019-6

Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL; BARI 2D Study Group. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Сohort. Diabetes Care. 2013 Oct;36(10):3208-3215. https://doi.org/10.2337/dc13-0012

Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-2293. https://doi.org/10.2337/dc10-1303

Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 Jun;29(6):1294-1299. https://doi.org/10.2337/dc06-0224

Sosenko JM, Gadia MT, Fournier AM, et al. Body stature as a risk factor for diabetic sensory neuropathy. Am J Med. 1986 Jun;80(6):1031-1034. https://doi.org/10.1016/0002-9343(86)90661-3

Clair C, Cohen MJ, Eichler F, Selby KJ, Rigotti NA. The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med. 2015 Aug;30(8):1193-1203. https://doi.org/10.1007/s11606-015-3354-y

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 Jan 27;352(4):341-350. https://doi.org/10.1056/nejmoa032782

Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009 Jun;35(3):206-213. https://doi.org/10.1016/j.diabet.2008.11.004

Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001 Aug;24(8):1448-1453. https://doi.org/10.2337/diacare.24.8.1448

Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014 Sep;37(9):2643-2646. https://doi.org/10.2337/dc14-0279

Bongaerts BW, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013 May;36(5):1141-1146. https://doi.org/10.2337/dc12-0744

Im S, Kim SR, Park JH, Kim YS, Park GY. Assessment of the medial dorsal cutaneous, dorsal sural, and medial plantar nerves in impaired glucose tolerance and diabetic patients with normal sural and superficial peroneal nerve responses. Diabetes Care. 2012 Apr;35(4):834-839. https://doi.org/10.2337/dc11-1001

Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 Mar;31(3):464-469. https://doi.org/10.2337/dc07-1796

Callaghan BC, Xia R, Banerjee M, de Rekeneire N, Harris TB, Newman AB, Satterfield S, Schwartz AV, Vinik AI, Feldman EL, Strotmeyer ES; Health ABC Study. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care. 2016 May;39(5):801-807. https://doi.org/10.2337/dc16-0081

Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain. 2009 Nov;146(1-2):34-40. https://doi.org/10.1016/j.pain.2009.06.001

Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain. 2014 Feb;155(2):367-376. https://doi.org/10.1016/j.pain.2013.10.023

Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004 Sep;21(9):976-982. https://doi.org/10.1111/j.1464-5491.2004.01271.x

Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006 Jul;29(7):1518-1522. https://doi.org/10.2337/dc05-2228

Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009 Mar;10(2):393-400. https://doi.org/10.1111/j.1526-4637.2008.00555.x

Vileikyte L, Leventhal H, Gonzalez JS, et al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care. 2005 Oct;28(10):2378-2383. https://doi.org/10.2337/diacare.28.10.2378

Vileikyte L, Rubin RR, Leventhal H. Psychological aspects of diabetic neuropathic foot complications: an overview. Diabetes Metab Res Rev. 2004 May-Jun;20 Suppl 1:S13-18. https://doi.org/10.1002/dmrr.437

Vinik E, Silva MP, Vinik AI. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011 Mar;40(1):97-109. https://doi.org/10.1016/j.ecl.2010.12.008

Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care. 2003 Mar;26(3):917-932. https://doi.org/10.2337/diacare.26.3.917

O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003 Mar;25(3):1017-1038. https://doi.org/10.1016/s0149-2918(03)80122-4

O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009 Oct;122(10 Suppl):S22-32. https://doi.org/10.1016/j.amjmed.2009.04.007

Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002 Oct;19(10):870-873. https://doi.org/10.1046/j.1464-5491.2002.00801.x

Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-173. https://doi.org/10.1016/s1474-4422(14)70251-0

Griebeler ML, Tsapas A, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis (Protocol). Systematic Reviews. 2012;1:61. https://doi.org/10.1186/2046-4053-1-61

Freeman R, Durso-DeCruz E, Emir B. Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy Findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008 Jul;31(7):1448-1454. https://doi.org/10.2337/dc07-2105

Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain. 2007;8(2):118-126. https://doi.org/10.1016/j.jpain.2006.06.005

Hurley R, Lesley M, Adams M, Brummett C and Wu C. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a metaanalysis. Reg Anesth Pain Med. 2008;33:389-394. https://doi.org/10.1016/j.rapm.2008.02.012

Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009 Feb 10;9:6. https://doi.org/10.1186/1471-2377-9-6

Zhang SS, Wu Z, Zhang LC, Zhang Z, Chen RP, Huang YH, Chen H. Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta-analysis. Acta Anaesthesiol Scand. 2015 Feb;59(2):147-159. https://doi.org/10.1111/aas.12420

Saldana M, Perez C, Navarro A, Masramon X and Rejas J. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. Clin Drug Investig. 2012;32:401-412. https://doi.org/10.2165/11599400-000000000-00000

Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”– a multinational, randomized, double-blind, parallel-

group study in patients with diabetic peripheral neuropathic pain. Pain. 2013 Dec;154(12):2616-25. https://doi.org/10.1016/j.pain.2013.05.043

Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008943. https://doi.org/10.1002/14651858.cd008943

Vasudevan D, Naik MM, Mukaddam QI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study. Ann Indian Acad Neurol. 2014 Jan;17(1):19-24. https://doi.org/10.4103/0972-2327.128535

Vileikyte L, Gonzalez JS. Recognition and management of psychosocial issues in diabetic neuropathy. Handb Clin Neurol. 2014;126:195-209. https://doi.org/10.1016/b978-0-444-53480-4.00013-8

Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013 May;35(5):612-23. https://doi.org/10.1016/j.clinthera.2013.03.008

Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998 Dec 2;280(21):1831-1836. https://doi.org/10.1001/jama.280.21.1831

Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005 Mar 31;352(13):1324-1334. https://doi.org/10.1056/nejmoa042580

Vileikyte L, Peyrot M, Gonzalez JS, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009 Jul;52(7):1265-73. https://doi.org/10.1007/s00125-009-1363-2

Vileikyte L, Peyrot M, Bundy C, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care. 2003 Sep;26(9):2549-55. https://doi.org/10.2337/diacare.26.9.2549

Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005 Jun;7(3):497-508. https://doi.org/10.1089/dia.2005.7.497

##submission.downloads##

Опубліковано

2017-06-26

Номер

Розділ

Новини та актуальна інформація